Product and Service Information

DYSPORT


Dysport reduces the appearance of lines that primarily affect the glabella, the area in between your eyebrows. These lines extend upward, or vertically, toward the forehead. They are especially noticeable when a person frowns.

While naturally occurring, with age glabella lines can become more prominent during times of relaxation too. This is because our skin loses collagen - the protein fibers responsible for elasticity.


While Dysport can help treat glabella wrinkles, it’s primarily meant for people who have either moderate or severe cases. Jess Jacob doesn't recommend the procedure to treat mild glabella lines. She can can help you tell the difference between mild and moderate wrinkles of this type.


If you’re considered a candidate for Dysport, the entire procedure is done at your Jess Jacob's office. No hospitalization is required, and you can leave immediately after the procedure is done.  Before the injections, she will apply a mild anesthetic. This helps to alleviate any pain felt during the procedure. For the treatment of frown lines, Jess typically injects 0.05 milliliters (mL) at a time in up to five portions around your eyebrows and forehead.


Dysport treats moderate to severe frown lines between the eyebrows by reducing specific muscle activity. Wrinkles are caused by repeated movements and muscle contractions, which means they can even develop in younger adults. One injection into each of 5 points between and above the eyebrows temporarily prevents muscle contractions that cause frown lines, leaving the rest of your face to move naturally. In other words, no frozen look, just natural-looking results. You can control your look instead of your look controlling you.


HOW LONG DOES DYSPORT LAST?

 The majority of users see improvement in just 2–3 days after treatment. In just one 10- to 20- minute treatment, Dysport may help improve the look of your frown lines between the eyebrows for up to 4 months.  Results of repeat treatments may be comparable to your first use. Another plus? There is minimal downtime after your treatment, which means you can get back to your day faster.


WHO SHOULD USE DYSPORT?

Stand up to those lines with Dysport. If you’re under 65 and seeking treatment to improve the look of wrinkles between your eyebrows, ask your specialist if Dysport is right for you. But before you begin, read below to help you make the safest, most informed decision.



XEOMIN


Xeomin (incobotulinumtoxinA), made by Merz Pharmaceuticals,  is approved by the US FDA for the treatment of adults with cervical dystonia or blepharospasm and Moderate to severe frown lines between the eyebrows.  IncobotulinumtoxinA is made from the bacteria that causes botulism. Botulinum toxin blocks nerve activity in the muscles, causing a temporary reduction in muscle activity.


A study cited in the Journal of Neurological Sciences on the efficacy and safety of XEOMIN found it showed “non-inferiority” to Botox when used in the same doses to treat cervical dystonia. It concluded that XEOMIN is a safe and effective treatment for the disorder.


Xeomin has also been approved for some cosmetic indications – moderate to severe frown lines between the eyebrows. Similiar to other drugs in this category, including Botox and Dysport, that also have approval for the treatment of facial wrinkles. Now that Xeomin is available and approved, doctors and nurse practitioners can use it both on-label and off-label to treat the same facial lines treated by Botox and Dysport, including frown lines, crow’s feet and forehead wrinkles.

Worldwide, more than 84,000 people have been treated with Xeomin injections. It is available in 50-unit and 100-unit vials.


BETTER OR WORSE THAN BOTOX?

Xeomin is the first neuromodulator that does not need to be refrigerated before use, which may simplify distribution. Xeomin is also has no additives, just botulinum toxin type A. This may mean that there is less risk of developing antibodies against Xeomin than other available neurotoxins. The body develops antibodies in response to a foreign invader and attacks. In theory, antibodies could prevent a neurotoxin from having its desired effects. The effects of Xeomin occur within one week, and the results last from three to six months, making it comparable to Botox in terms of both onset and duration of action. Xeomin should not be used interchangeably with other botulinum products.


ARE THERE ANY RISKS?

There is a risk that all botulinum toxin products may spread from the area where they were injected to other parts of the body, causing potentially life-threatening swallowing and breathing problems. This was predominantly seen in children treated with Botox off-label for cerebral palsy. These issues have not been reported among people who received botulinum products for cosmetic uses or to treat blepharospasm.


Other risks may include bleeding and bruising at the injection site and allergic reactions such as itching, swelling or shortness of breath. Your doctor should discuss all the potential risks of this procedure with you during your consultation.

When Xeomin is used to treat cervical dystonia, side effects include neck pain, muscle weakness, injection site pain and musculoskeletal pain. When used to treat blepharospasm, the most common side effects of Xeomin were eyelid sagging, dry eye, dry mouth, diarrhea, headache, visual impairment, shortness of breath (dyspnea), and upper respiratory infections.


FACTS

Botulinum toxin injections (e.g., Xeomin, Dysport) are the most commonly performed facial rejuvenation procedure in the U.S. In 2015, 6.7 million Botox procedures were performed, up 759 percent since 2000, according to the American Society of Plastic Surgeons. Botox has been found to treat true medical conditions (outside of facial wrinkles) such as spastic bladder, migraines and spasms of the eyelid. Often, children receive Botox for what we call “therapeutic” indications, around 400 units at any one given time. For most of us receiving Botox for our wrinkles, the typical dose is 20-70 units, far less than what is given for therapeutic indications.